Bayer's Ruveon Bet: Legal Relief and Trade Fireworks Fuel a Record Run, But RSI Flashes Red
Published on 07/04/2026 at 15:24 | Redaktion boerse-global.de
A 7-2 Supreme Court ruling handed Bayer a seismic legal victory in the Monsanto v. Durnell case, ruling that federal law preempts state-level failure-to-warn claims — the legal foundation beneath roughly 200,000 glyphosate lawsuits. Rather than resting on the verdict, the Leverkusen group moved quickly to crystallise the advantage, carving its entire US glyphosate business into a newly incorporated subsidiary called Ruveon LLC. The entity will control pricing, production and distribution, isolating the most contentious part of Bayer’s portfolio.
Market participants seized the restructuring as the clearest signal yet that a full breakup of the conglomerate is on the table. Deutsche Bank analysts upgraded the stock to “Buy” with a €60 price target, arguing that a dismantling of Bayer’s business lines is no longer hypothetical. The carve-out, they said, is a deliberate step toward either a spin-off or outright sale of the glyphosate division, further shielding the parent from legacy litigation.
The equity responded explosively. On Thursday alone, Xetra-listed shares jumped 8.9% to €53.36, piercing the €50 barrier for the first time since autumn 2023. By the Friday close the stock stood at €53.04, within 1.5% of a fresh 52-week high of €53.86 hit on 3 July. The numbers behind the rally are startling: 53.74% over 30 days, 13.80% in the past week alone, 39.49% year-to-date, and a blistering 103.41% over twelve months. Bayer now sits third in the DAX year-to-date ranking, behind only Infineon and Hochtief.
Should investors sell immediately? Or is it worth buying Bayer?
Yet the strategic manoeuvring has opened a second, less celebrated front. Bayer, together with Ruveon, filed an anti-dumping petition with the US Department of Commerce, the USITC and the Court of International Trade, targeting Chinese glyphosate imports. The move has angered US farm groups — many of which had supported Bayer during the Supreme Court fight — who warn that protectionist tariffs will raise input costs for American agriculture. The irony is not lost: within weeks of escaping the courtroom, Bayer now faces a political trade battle against its own former allies.
Technicians are sounding a cautious note amid the euphoria. The 14-day relative strength index has climbed to 85.1, firmly in overbought territory. Annualised volatility over the past 30 days stands at 63.19%, and the stock trades a remarkable 36.50% above its 50-day moving average and 42.91% above the 200-day average — spreads that suggest the rally has detached decisively from the underlying trend.
Investors have two key events on the horizon. On 4 August, Bayer releases second-quarter figures, offering the first look at how Ruveon’s operations are affecting the income statement. Then, on 19 August, a US court will rule on final approval of the multibillion-dollar settlement that the company has already negotiated with claimants. Both dates could reinforce the narrative of a cleaner, less litigious Bayer — or expose cracks in the recovery.
For now, the stock is caught between an unusually favourable structural shift and one of the most extreme overbought readings in recent memory. The Supreme Court opened the door, Ruveon walked through it, and the anti-dumping petition keeps the timing tricky. Whether the rally has enough room to run or is approaching a technical speed bump will be answered in the coming weeks.
Ad
Bayer Stock: New Analysis - 4 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
